Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
Christine Benn Christiansen1, Christian Torp-Pedersen1, Lars Køber21Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; 2Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkBackground: Dronedarone has been developed...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-03-01
|
| Series: | Clinical Interventions in Aging |
| Subjects: | |
| Online Access: | https://www.dovepress.com/impact-of-dronedarone-in-atrial-fibrillation-and-flutter-on-stroke-red-peer-reviewed-article-CIA |
| _version_ | 1818926498799681536 |
|---|---|
| author | Christine Benn Christiansen Christian Torp-Pedersen Lars Køber |
| author_facet | Christine Benn Christiansen Christian Torp-Pedersen Lars Køber |
| author_sort | Christine Benn Christiansen |
| collection | DOAJ |
| description | Christine Benn Christiansen1, Christian Torp-Pedersen1, Lars Køber21Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; 2Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkBackground: Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse effects as amiodarone.Objective and methods: This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA and ATHENA).Results: The target dose for dronedarone was established in the DAFNE study to be 400 mg twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with severe heart failure was discontinued because of increased mortality in dronedarone group. Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on placebo (crude rate 2.5%), respectively.Conclusion: Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke in patients with AF who receive usual care, which includes antithrombotic therapy and heart rate control.Keywords: atrial fibrillation, stroke, dronedarone |
| first_indexed | 2024-12-20T02:58:05Z |
| format | Article |
| id | doaj.art-b2df60974a944269a1727fa752655126 |
| institution | Directory Open Access Journal |
| issn | 1178-1998 |
| language | English |
| last_indexed | 2024-12-20T02:58:05Z |
| publishDate | 2010-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Interventions in Aging |
| spelling | doaj.art-b2df60974a944269a1727fa7526551262022-12-21T19:55:50ZengDove Medical PressClinical Interventions in Aging1178-19982010-03-01Volume 563694145Impact of dronedarone in atrial fibrillation and flutter on stroke reductionChristine Benn ChristiansenChristian Torp-PedersenLars KøberChristine Benn Christiansen1, Christian Torp-Pedersen1, Lars Køber21Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; 2Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkBackground: Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse effects as amiodarone.Objective and methods: This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA and ATHENA).Results: The target dose for dronedarone was established in the DAFNE study to be 400 mg twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with severe heart failure was discontinued because of increased mortality in dronedarone group. Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on placebo (crude rate 2.5%), respectively.Conclusion: Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke in patients with AF who receive usual care, which includes antithrombotic therapy and heart rate control.Keywords: atrial fibrillation, stroke, dronedaronehttps://www.dovepress.com/impact-of-dronedarone-in-atrial-fibrillation-and-flutter-on-stroke-red-peer-reviewed-article-CIAAntiarrhythmic therapyatrial fibrillationDronedaronestroke |
| spellingShingle | Christine Benn Christiansen Christian Torp-Pedersen Lars Køber Impact of dronedarone in atrial fibrillation and flutter on stroke reduction Clinical Interventions in Aging Antiarrhythmic therapy atrial fibrillation Dronedarone stroke |
| title | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| title_full | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| title_fullStr | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| title_full_unstemmed | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| title_short | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| title_sort | impact of dronedarone in atrial fibrillation and flutter on stroke reduction |
| topic | Antiarrhythmic therapy atrial fibrillation Dronedarone stroke |
| url | https://www.dovepress.com/impact-of-dronedarone-in-atrial-fibrillation-and-flutter-on-stroke-red-peer-reviewed-article-CIA |
| work_keys_str_mv | AT christinebennchristiansen impactofdronedaroneinatrialfibrillationandflutteronstrokereduction AT christiantorppedersen impactofdronedaroneinatrialfibrillationandflutteronstrokereduction AT larskoslashber impactofdronedaroneinatrialfibrillationandflutteronstrokereduction |